Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial
There were slight differences in the mean C<sub>max</sub>, C<sub>min</sub>, AUC<sub>tau</sub> and C<sub>av</sub> between the three-week dosing group and the single-week dosing group, and the mean steady-state concentrations of C<sub>av</sub> were comparable; however, there were no differences in efficacy, safety or immunogenicity between the two groups.
Authors
- Xiuli Yang (ORCID: https://orcid.org/0000-0001-6111-9927)
- Ning Xie
- Jian Huang (ORCID: https://orcid.org/0000-0001-8117-1028)
- Wenming Cao
- Xinshuai Wang (ORCID: https://orcid.org/0000-0002-4097-098X)
- Xiaojia Wang
- Shaoping Chen (ORCID: https://orcid.org/0000-0003-0027-1276)
- Yuru Chen (ORCID: https://orcid.org/0000-0003-1508-3593)
- Zhanhong Chen (ORCID: https://orcid.org/0000-0003-1802-6375)
- Lu Gan (ORCID: https://orcid.org/0000-0003-4116-8830)
- Quchang Ouyang (ORCID: https://orcid.org/0000-0003-1233-6081)
- Xiying Shao (ORCID: https://orcid.org/0000-0003-3547-3628)
- Hua Yang (ORCID: https://orcid.org/0000-0001-7706-9020)
- Yabing Zheng (ORCID: https://orcid.org/0000-0002-4835-4399)
Institutions
- Wenzhou Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- Hunan Cancer Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- First Affiliated Hospital of Henan University of Science and Technology (CN)
- Nanyang Medical College (CN)
- Heze Municipal Hospital (CN)
- Affiliated Hospital of Hebei University (CN)
- Dongyang People's Hospital (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Journal of Translational Internal Medicine
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1515/jtim-2024-0022
- Citations
- 17
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 4.80